ERBB2 and breast carcinoma: The BELLE-2 study (Clinicaltrials.gov no: NCT01610284) is a phase III trial which randomised 1,148 postmenopausal women with HR+/HER2- advanced breast cancer after progression on AI to fulvestrant and buparlisib or fulvestrant and placebo; preliminary results may soon be available.